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savings and compliance programs at those who need them the
most.
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THE EFFECTS OF NONCOMPLIANT COST-CUTTING
BEHAVIORS ON OUTCOMES AMONG ADULTS INTHE
UNITED STATES
Bolge SC, Kannan H
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To quantify the effects of noncompliant cost-
cutting behavior on health-related quality of life (HRQOL),
work productivity, and activity impairment among U.S. adults.
METHODS: Data were from quarters one and two of the 2007
National Health and Wellness Survey (NHWS), an internet-
based study of the health care attitudes, behaviors, disease states,
and outcomes of a demographically representative sample of
adults age 18+. Noncompliant cost-cutting behaviors were
deﬁned as taking less medication than prescribed, cutting tablets
in half, or buying fewer tablets. Outcomes measures include the
SF12V2 and the Work Productivity and Activity Impairment
(WPAI) questionnaire. Linear regression analysis was used to
control for gender, age, race, marital status, education, and
comorbid conditions. RESULTS: Of the 42,010 NHWS respon-
dents, 7% took less medication than prescribed, 6% cut tablets
in half, and 2% bought fewer tablets. Controlling for potential
confounders, SF12 physical and mental summary scores are sig-
niﬁcantly lower for those taking less medication (2.3 and 2.5
points lower, p < 0.001), those cutting tablets in half (0.9 and 1.1
points, p < 0.001), and those buying fewer tablets (1.5 and 1.6,
p < 0.001). Controlling for potential confounders, WPAI overall
work loss and WPAI activity impairment are signiﬁcantly lower
for those taking less medication (10.3 and 7.2 points lower,
p < 0.001), those cutting tablets in half (11.2 and 5.3 points, p <
0.001), and those buying fewer tablets (15.8 and 8.2, p < 0.001).
CONCLUSION: Noncompliant cost-cutting behavior negatively
affects humanistic outcomes. By decreasing this behavior cost
savings and compliance programs should have a positive effect
on humanistic outcomes.
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OBJECTIVE: To quantify the effects of noncompliant cost-
cutting behavior on health-related quality of life (HRQOL),
work productivity, and activity impairment among adults in
Europe. METHODS: Data were from the 2007 European
National Health and Wellness Survey (NHWS), a self-
administered, Internet-based study of the health care attitudes,
behaviors, disease states, and outcomes of a demographically
representative sample of adults age 18+ across ﬁve European
countries: France, Germany, Italy, Spain, and the UK. Three
noncompliant cost-cutting behaviors were analyzed: taking less
medication than prescribed, cutting tablets in half, and buying
fewer tablets. Outcomes measures included the SF12V2 and the
Work Productivity and Activity Impairment (WPAI) question-
naire. Linear regression analysis was used to adjust for gender,
age, country of residence, marital status, education, and physi-
cal and psychiatric comorbid conditions. RESULTS: Of the
53,524 NHWS respondents, 3.1% took less medication than
prescribed, 2.1% cut tablets in half, and 1.6% bought fewer
tablets. Unadjusted results showed a negative association
between these behaviors and indirect costs. Adjusting for
potential confounders, SF12 physical and mental summary
scores were signiﬁcantly lower for those taking less medication
(2.2 and 2.4 points lower, p < 0.001), those cutting tablets in
half (1.8 and 2.0 points lower, p < 0.001), and those buying
fewer tablets (1.8 and 2.3 points lower, p < 0.001). Adjusting
for potential confounders, WPAI overall work loss and WPAI
activity impairment were signiﬁcantly lower for those taking
less medication (11.0 and 9.2 points lower, p < 0.001), those
cutting tablets in half (13.4 and 6.3 points lower, p < 0.001),
and those buying fewer tablets (10.1 and 7.7 points lower,
p < 0.001). CONCLUSION: Noncompliant cost-cutting behav-
ior negatively affects indirect costs, speciﬁcally HRQOL, work
productivity, and activity impairment. By decreasing this behav-
ior cost savings and compliance programs should have a posi-
tive effect on humanistic outcomes.
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UNITED STATES PHYSICIANS AND IN-OFFICE DRUG
ADMINISTRATION:THE CONCEPT OF “INCIDENT-TO”
SERVICES
Pierce CA1, Baker JJ2
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OBJECTIVE: The U.S. Centers for Medicare and Medicaid Ser-
vices (CMS) generally pays for non-institutional-based services
and supplies “incident to” a physician’s professional service. This
study explores the concept of incident-to, the regulations and
guidance surrounding its use and presents practical consider-
ations for physicians. METHODS: Incident-to guidance pro-
vided by CMS was collected, arranged in order of issuance,
abstracted and analyzed. A compilation of relevant resources, a
glossary and checklist tool were also created as part of the
project. RESULTS: Federal regulations at 42 CFR 410.26(b)
specify criteria for “incident to” services. Medicare Part B pays
for services and supplies incident to the service of a physician,
including drugs or biologicals that are not usually self-
administered. The services and supplies must be furnished in a
non-institutional setting to non-institutional patients and be of
an integral, though incidental, part of the service of a physician
in the course of diagnosis or treatment of an injury or illness.
They are also provided without charge or included in the bill of
a physician. Such services are typically performed by non-
physician staff however require direct personal supervision by the
physician. The U.S Ofﬁce of the Inspector General (OIG) has
announced incident-to services as an area of study in their 2008
Work Plan. CONCLUSION: The concept of incident-to services
is commonly misunderstood and may therefore present a Medi-
care compliance risk for physicians. It is essential for physicians
and their practice decision-makers to understand and apply the
CMS regulations surrounding incident-to services in order to
appropriately bill and be reimbursed by Medicare for the provi-
sion of Part B separately payable drugs in non-institutional
settings.
HEALTH CARE USE & POLICY STUDIES—
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Cascade EF1, Stephenson H2
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OBJECTIVE: With the withdrawal of Zelnorm, recall of prod-
ucts such as Ranbaxy’s generic gabapentin, and the increase in
Abstracts A31
FDA safety communications related to highly prescribed prod-
ucts including the thiazolidinediones and bisphosphonates in
2007, information on drug safety was present weekly, if not
daily, in the newspaper and on television. To assist consumers in
understanding their risk of developing serious side effects and put
into context the relative risk of their various medications, we
have developed a 5-color drug risk rating system. METHODS:
The iGuard Risk Rating system is a patented process for sum-
marizing serious adverse events contained in each medication’s
Prescribing Information. Speciﬁcally, we focus on: 1) the severity
of the reaction (serious disability or death); 2) the likelihood of
the reaction (e.g., >1 in 10,000); and 3) proportion of the popu-
lation affected (e.g., 0–15%). We also adjust for lack of experi-
ence with a product on the market: <1,000,000 prescriptions or
<2 years post-launch. Our iGuard Risk Ratings, from lowest to
highest, are as follows: 1) Green: Low Risk–Suitable for wide-
spread use; 2) Blue: General Risk–Use under normal care of a
doctor; 3) Yellow: Guarded–Be on the lookout for safety events;
4) Orange: Elevated Risk–Create a personal risk reduction plan
with your doctor; and 5) Red: High Risk–Requires careful con-
sideration of risk versus beneﬁt. RESULTS: To date, we have
rated 106 medications. Risk Ratings associated with individual
medications are available on the project website at www.i-
guard.org. A total of 80 of 106 medications (75%) were rated
Level 2/Blue: General Risk. An additional 20% were rated Level
4/Orange: Elevated Risk. Ratings across molecules within a
therapeutic class are very similar. CONCLUSION: Consumer
feedback on the iGuard Risk Ratings has been very positive,
especially in understanding which of their medications they need
to be most diligent in monitoring.
PHP11
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OBJECTIVE: Ethnic disparities in hospital discharges against
medical advice (AMA) have been examined in previous studies.
However, the institutional factors affecting health decision
making have received much less attention. This study examines
the evidence for a joint impact of ethnicity and hospital quality
on the likelihood of a discharge AMA in patients with cardio-
vascular disease (CVD). METHODS: Adult patients hospitalized
with a primary admissions diagnosis of CVD from 2000 to 2005
were identiﬁed in a state-wide conﬁdential inpatient hospital
discharge dataset. The dataset was augmented with information
from several sources, including the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO). A high
quality hospital was deﬁned as a hospital whose performance
exceeded the state average on each JCAHO hospital performance
measure. A hierarchical generalized linear logistic model of a
discharge against medical advice controlling for various indi-
vidual and contextual factors was estimated using cross-sectional
data. RESULTS: A total of 2593 of the 328,342 hospitalizations
for CVD (0.8%) resulted in a discharge AMA. The patients
self-identiﬁed as non-caucasian in thirty percent (N = 100,074)
of the hospitalizations. Fifteen percent (N = 48,177) of the hos-
pitalizations occurred in high quality hospitals. The adjusted
odds of a discharge AMA in a low quality hospital were lower for
non-Caucasians (OR = 0.74; p = 0.0005) compared to Cauca-
sians while the adjusted odds of a discharge AMA in a high
quality hospital were unchanged between Caucasians and
non-Caucasians (OR = 0.95; p = 0.6). Among Caucasians, a dis-
charge AMA was less likely (OR = 0.75; p = 0.01) at a high
quality hospital compared to a low quality hospital while, among
non-Caucasians, the odds of a discharge AMA were unchanged
(OR = 0.96; p = 0.74) across hospital quality groups. CONCLU-
SION: The two unique and complementary ﬁndings here are
that: 1) institutional quality mediates the relationship between
ethnicity and hospital discharges AMA; and 2) the relationship
between hospital quality and discharges AMA varies with
ethnicity.
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ASSOCIATION BETWEEN DIRECT-TO-CONSUMER
ADVERTISING (DTCA) AND DRUG UTILIZATION INTHE
U.S. MEDICAID MARKET FOR SELECTED DRUG CLASSES
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OBJECTIVE: Spending on direct-to-consumer advertising
(DTCA) has seen exponential growth since the late 1990s. The
purpose of this research was to assess the association between
DTCA spending and drug utilization and reimbursement in
the U.S. Medicaid market. METHODS: National direct-to-
consumer advertising expenditures were obtained from Advertis-
ing Age for selected brands in three drug classes: HMG Co-A
reductase inhibiting agents (statins), anti-ulcer/GERD medica-
tions, and antidepressants. The drug utilization and reimburse-
ment (sales) data were extracted from the national Medicaid
pharmacy ﬁles provided by the Centers for Medicare & Medicaid
Services. The annual advertising expenditures, drug utilization,
and reimbursement were charted from 2000 to 2005. Correla-
tion analysis was used to assess the association between both
contemporaneous and lagged DTCA spending by pharmaceutical
companies and drug utilization and reimbursement for each of
the three therapeutic classes. RESULTS: A wide range of esti-
mated Pearson correlation coefﬁcients were derived, including
some negative coefﬁcients. The strongest positive correlations
were found for the statins and antidepressants for the year 2003.
Only antidepressants had a statistically signiﬁcant correlation
(r = 0.58, p < 0.05) between DTCA and reimbursement/
utilization based on a pooled correlation analysis from 2000 to
2005. CONCLUSION: Utilization rates and reimbursement in
the Medicaid market for the investigated medications were not
consistently statistically impacted by DTCA. While there is evi-
dence of a strong correlation for antidepressants, there is less
compelling evidence for statins, and none for the anti-ulcer
drugs. Although both utilization and expenditures in Medicaid
were growing for all three classes, their growth was due to
factors beyond DTCA.
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OBJECTIVE: To describe the amount and types of unused con-
trolled substances (CS) at the time of death in home hospice and
to describe methods used by hospice nurses to destroy CS after
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